prikaz prve stranice dokumenta Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)
  Preuzmi
PDF 318.45 KB
Znanstveni rad - Izvorni znanstveni rad
Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)
Cancer Biomarkers, 30 (2021), 1; 95-104. https://doi.org/10.3233/CBM-201497
Sirotković-Skerlev, Maja; Plavetić, Natalija Dedić; Sedlić, Filip; Kuna, Sanja Kusačić; Vrbanec, Damir; Belev, Borislav; Pleština, Stjepko; Kovač, Zdenko; Kulić, Ana

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Sirotković Skerlev, M., Plavetić, N. D., Sedlić, F., Kuna, S. K., Vrbanec, D., Belev, B. ... Kulić, A. (2021). Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years). Cancer Biomarkers, 30. (1), 95-104. doi: 10.3233/CBM-201497

Sirotković Skerlev, Maja, et al. "Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)." Cancer Biomarkers, vol. 30, br. 1, 2021, str. 95-104. https://doi.org/10.3233/CBM-201497

Sirotković Skerlev, Maja, Natalija Dedić Plavetić, Filip Sedlić, Sanja Kusačić Kuna, Damir Vrbanec, Borislav Belev, Stjepko Pleština, Zdenko Kovač i Ana Kulić. "Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)." Cancer Biomarkers 30, br. 1 (2021): 95-104. https://doi.org/10.3233/CBM-201497

Sirotković Skerlev, M., et al. (2021) 'Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)', Cancer Biomarkers, 30(1), str. 95-104. doi: 10.3233/CBM-201497

Sirotković Skerlev M, Plavetić ND, Sedlić F, Kuna SK, Vrbanec D, Belev B, i sur.. Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years). Cancer Biomarkers [Internet]. 2021. [pristupljeno 22.11.2024.];30(1):95-104. doi: 10.3233/CBM-201497

M. Sirotković Skerlev, et al., "Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)", Cancer Biomarkers, vol. 30, br. 1, str. 95-104, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:834430. [Citirano: 22.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:834430
Podaci o radu
Naslov (engleski)Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)
AutorMaja Sirotković-Skerlev
AutorNatalija Dedić Plavetić
AutorFilip Sedlić
AutorSanja Kusačić Kuna
AutorDamir Vrbanec
AutorBorislav Belev
AutorStjepko Pleština
AutorZdenko Kovač
AutorAna Kulić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PATOFIZIOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patofiziologija
Sažetak (engleski)
BACKGROUND: Apoptosis inhibition is a major tumorigenic factor. Bcl-2 dysregulation and TP53 mutation status, which may correlate with autoantibody generation, contribute to impaired apoptosis. ----- OBJECTIVE: This study aimed to investigate the prognostic value of circulating Bcl-2 and anti-p53 antibodies (p53Abs) in a 17.5-year follow-up of breast cancer patients. We also analysed the correlations of Bcl-2 and p53Abs with various clinicopathological parameters in order to assess their impact on tumor aggressiveness. ----- METHODS: Serum Bcl-2 and p53Abs levels were analysed by the enzyme-linked immunosorbent assay (ELISA) in 82 patients with invasive breast cancer and twenty individuals without malignancy. ----- RESULTS: Serum Bcl-2 and p53Abs levels in breast cancer patients were significantly higher than those in controls. Patients with high levels of Bcl-2 (cut-off 200 U/ml) had a poorer prognosis (17.5-year survival) than those with lower Bcl-2 values. In combined analysis the subgroup of patients with elevated p53Abs (cut-off 15 U/ml) and elevated Bcl-2 (cut-offs 124 U/ml and 200 U/ml) had the worse prognosis in 17.5-year survival. In correlation analysis p53Abs and Bcl-2 were associated with unfavorable clinicopathological parameters. ----- CONCLUSIONS: Our results suggest that breast cancer patients with high serum levels of p53Abs and Bcl-2 present an especially unfavorable group in a long follow-up.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaCancer Biomarkers
Brojčani podacivol. 30, br. 1, str. 95-104
p-ISSN1574-0153
e-ISSN1875-8592
DOIhttps://doi.org/10.3233/CBM-201497
URN:NBNurn:nbn:hr:105:834430
Datum objave publikacije2021
URL dokumentahttps://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/CBM-201497
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2021-04-21 14:34:32